Sanford C. Bernstein Initiates Coverage on Novo Nordisk A/S (NYSE:NVO)

Equities researchers at Sanford C. Bernstein initiated coverage on shares of Novo Nordisk A/S (NYSE:NVO) in a note issued to investors on Wednesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $175.00 price target on the stock. Sanford C. Bernstein’s price target suggests a potential upside of 372.31% from the stock’s current price.

Several other research firms have also weighed in on NVO. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. The Goldman Sachs Group reissued a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. HSBC reissued a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Citigroup assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. Four investment analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Stock Performance

NVO stock opened at $37.05 on Wednesday. The firm has a 50 day moving average of $48.67 and a two-hundred day moving average of $51.29. Novo Nordisk A/S has a 12 month low of $35.85 and a 12 month high of $81.44. The company has a market capitalization of $165.44 billion, a price-to-earnings ratio of 10.68 and a beta of 0.73. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quotient Wealth Partners LLC grew its position in Novo Nordisk A/S by 2.0% in the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after acquiring an additional 177 shares in the last quarter. Certuity LLC lifted its position in shares of Novo Nordisk A/S by 3.6% during the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after purchasing an additional 177 shares in the last quarter. Beacon Financial Group boosted its stake in shares of Novo Nordisk A/S by 4.3% in the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after purchasing an additional 178 shares during the period. Oakworth Capital Inc. boosted its stake in shares of Novo Nordisk A/S by 41.6% in the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after purchasing an additional 182 shares during the period. Finally, True North Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after purchasing an additional 199 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves higher‑dose Wegovy (Wegovy HD), showing ~20.7% mean weight loss in the STEP UP trial — approval moved through an accelerated priority pathway and Novo expects a U.S. launch in April 2026, giving the company a stronger product to regain share vs. rivals. FDA approves Novo Nordisk’s new Wegovy® HD injection
• Positive Sentiment: Sell‑side catalyst: Sanford C. Bernstein initiated coverage with an “outperform” and a high $175 PT, signaling potential upside and providing a supporting narrative for long‑term investors.
• Positive Sentiment: Real‑world retention tailwind — a study flagged that stopping GLP‑1s raises cardiovascular risks, which supports chronic use and could bolster prescription persistence for Wegovy and related products. Stopping GLP-1s raises risk of heart attack, stroke and death, study says
• Positive Sentiment: Novo is expanding access efforts in Japan (self‑pay pathways), which could add incremental revenue in a large underpenetrated market. Novo Nordisk Seeking to Expand Weight-Loss Drugs Access in Japan
• Positive Sentiment: Pipeline diversification: positive Phase‑2 data for investigational obesity candidate UBT251 (triple agonist) adds another growth option beyond semaglutide. Novo Nordisk Obesity Drug Data Sparks Questions On Valuation And Momentum
• Negative Sentiment: Patent expiration on semaglutide in India this week opens the door to low‑cost generics and potential share/pricing erosion in a large market — a clear near‑term revenue risk in that geography. Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
• Negative Sentiment: Competitive pressure intensifies — Eli Lilly confirmed superior weight‑loss with next‑gen candidate retatrutide, and Roche is re‑entering obesity, raising the risk of share loss and pricing pressure over time. Eli Lilly Confirms ‘Superior Weight Loss’ Of Its Next-Generation Obesity Drug

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.